The present invention relates to humanized calcitonin mimetics and their use in treating diabetes (Type I and / or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoidarthritis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poor regulation of food intake.